Buy Laknet pills 75 mcg, 28 pcs
  • Buy Laknet pills 75 mcg, 28 pcs


Gedeon Richter
1825 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Laktinet is a gestagen-containing oral contraceptive, the active ingredient of which is desogestrel. Like other hormonal contraceptives, which include exclusively progestogen as an active ingredient, Lactinet can be taken by women during breastfeeding, as well as if there are contraindications to estrogen or unwillingness to use estrogen-containing contraceptives.
Unlike other progestin contraceptives, the contraceptive effect of Lactinet is due to inhibition of the ovulation process, as evidenced by the absence of an ovulatory follicle during an ultrasound study and the lack of elevation of luteotropic hormone (LH) and progesterone in the serum in the middle of the menstrual cycle. At the same time, desogestrel, as well as other progestogens, has the ability to increase the viscosity of the cervical mucus, preventing the promotion of sperm.

The Pearl Index (a measure reflecting the onset of pregnancy in 100 women during a year of contraception) is 0.4, which is comparable with the use of combined hormonal contraceptives for oral use. The use of the drug Laktinet leads to a decrease in the content of estradiol in the blood plasma to the values ​​corresponding to the early follicular phase. Progestogens affect carbohydrate and lipid metabolism.

When ingestion, desogestrel is absorbed quickly. The average maximum concentration in serum is reached after 1.8 hours (Tmax) after taking the pill. Bioavailability of etonogestrel is about 70%.
Distribution in the body
Etonogestrel in 95.5-99% binds to plasma proteins, mainly albumin and to a lesser extent with sex hormone-binding globulin (SHBG).
Desogestrel by hydroxylation and dehydrogenation is metabolized to the active metabolite etonogestrel. Etonogestrel is metabolized by the formation of sulfate and glucuronide conjugates.
Excretion from the body
The average elimination half-life of etonogestrel is about 30 hours, both in single and multiple doses. Equilibrium plasma concentrations are established after 4-5 days. Etonogestrel and its metabolites are excreted by the kidneys and through the intestines (in the ratio 1.5: 1) in the form of free steroids and conjugates.
In nursing mothers, etonogestrel is excreted in breast milk in a milk / serum ratio of 0.37-0.55. Thus, with an approximate consumption of mother's milk in the amount of 150 mg / kg / day, the newborn can receive 0.01-0.05 mcg etonogestrel per kg of body weight per day.




Each tablet contains:
Active substance: desogestrel 0.075 mg;
composition of the tablet core: DL-α-tocopherol, colloidal silicon dioxide, stearic acid, magnesium stearate, potato starch, povidone K30. lactose monohydrate;
shell composition: opadry II white (titanium dioxide (EI71). C1 77891, talc, macrogol 3000, polyvinyl alcohol).

Desogestrel is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Laknet Gedeon Richter Hungary pills
Charozetta N.V.Organon Netherlands pills

No customer reviews for the moment.

Write your review

Write your review


Dosage and Administration

In the absence of previous use of hormonal contraceptives (during the last month), taking pills starts from the first day of the menstrual cycle, one tablet per day, if possible at the same time of day, following the direction indicated on the package so that the interval between taking two pills should be 24 hours, if necessary with a small amount of liquid. This drug does not require a break in the reception. Each subsequent packaging should begin immediately after the end of the previous one.

First dose
Women who in the previous month did not take oral contraceptives:
Reception of the first pill should begin from the first day of the menstrual cycle (menstruation). In this case, the use of additional methods of contraception is not required.
The pill can be started from 2-5 days of menstruation, but in this case, in the first cycle, you need to use additional methods of contraception in the first 7 days of taking the pills.
Women who are switching from another oral oral contraceptive pill (CPC) to Lactinet®
If possible, the next day after taking the last tablet of the previous PDA. In this case, the use of additional methods of contraception is not required.

Women who are switching from monocomponent preparations containing progestogen only (mini-pili, injections, implants or intrauterine contraceptives that release progestogen)
When you switch from mini-pill, you can start taking the drug on any given day; in the case of injections, on the day when another injection should be given; in the case of an implant, the day after its removal.
In all these cases, the use of barrier methods of contraception is recommended for the first 7 days.

Taking the drug after an abortion in the first trimester of pregnancy
After an abortion in the first trimester of pregnancy, it is recommended to start taking the drug immediately after the abortion, and in this case there is no need to use additional methods of contraception.
Taking the drug after childbirth, or after termination of a second trimester pregnancy
Taking the drug start no earlier than 21-28 days after termination of pregnancy in the second trimester or after childbirth. If taking the drug is supposed to start later, then it is necessary to use a barrier method of contraception during the first 7 days. In addition, if unprotected sexual intercourse took place before the start of the drug use, it is necessary to exclude pregnancy or postpone the start of the drug on the first day of the next menstruation (when the menstrual cycle is restored).

Missed (forgotten) pills
The effectiveness of a contraceptive is reduced if more than 36 hours have passed between taking two pills. If a break does not exceed 12 hours, the contraceptive effect is not reduced, and the use of an additional contraceptive method is not required.
Acceptance of the remaining pills continue on the usual schedule.
In the case of more, than the 12-hour break, the contraceptive effect may be reduced.
To achieve effective blockage of the hypothalamic-pituitary-ovarian system, it is necessary to take the drug daily for 7 days. In this way, with a break longer than 12 hours, the drug is continued as usual, however, in the next 7 days it is necessary to use additional (barrier) methods of contraception. If the pill was missed in the first week of the drug use and unprotected sexual intercourse took place in the previous 7 days, then the probability of pregnancy may not be excluded.

Measures taken in case of vomiting
If vomiting develops within 3-4 hours after taking the pill, the pill is not completely absorbed. In this case, you should do the same as in the case of missed pills.The required tablet (required pills) should be replenished from another package.

Despite the regular intake of pills, there may be irregular menstruation. If menstruation occurs very often and irregularly, you should consider using another method of contraception. If the disorder persists, it is necessary to eliminate the organic cause.
The tactics for amenorrhea that occurred during the use of the drug depends on whether the pills were taken in accordance with the instructions or not; may require a pregnancy test.
If pregnancy occurs, the drug should be stopped.
It must be remembered that taking Lactinet® does not protect against HIV infection (AIDS) and other sexually transmitted diseases.

Adverse reactions

The most frequent adverse effect reported in clinical studies was irregular menstruation. Up to 50% of women using desogestrel noted acyclic bleeding: in 20–30% of women, menstruation becomes more frequent, while in the other 20% it is less common or even completely stopped. Menstruation may also be longer.

After several months of taking the drug, menstruation tends to become less frequent. Informing the physician, observation by the physician, and the use of the menstrual diary can increase compliance during treatment with the drug.

The following are undesirable effects that have an established, probable or possible association with the use of the drug.

If any of the following conditions / risk factors are observed, the expected benefits and the risk of using a contraceptive should be carefully weighed when consulting with your doctor throughout the entire period of contraception. When any of the following conditions / risk factors appear, increase, or change, the patient should immediately consult a doctor to decide on the possibility of further use of the drug.

Often - acne, nausea, mood changes, decreased libido, breast tenderness, menstrual disorders, headache, weight gain.

Infrequently - alopecia, fatigue, vomiting, discomfort when wearing contact lenses, vaginitis, dysmenorrhea, ovarian cysts.

Seldom - skin redness, rash, urticaria, erythema nodosum.

Although a reliable connection with the intake of gestagens has not been established, cholestatic jaundice, pruritus, cholelithiasis, chorea, herpes of pregnancy, otosclerosis, deafness, and the development of hemolytic-uremic syndrome are possible.



  • Resistant arterial hypertension, developing on the background of taking the drug, including the ineffectiveness of antihypertensive therapy.
  • Chloasma, especially in the presence of chloasma during pregnancy in history.
  • Diabetes mellitus (due to the possible effect of progestogens on peripheral insulin resistance and glucose tolerance).
  • Porphyria.
  • Systemic lupus erythematosus (SLE).
  • Herpes (during pregnancy in history).

Drug interactions

The simultaneous use of drugs, inducers of liver microsomal enzymes, can cause breakthrough bleeding and a decrease in the contraceptive effect of the drug. These drugs are derivatives of hydantoin (including phenytoin, rifabutin, barbiturates, primidone, carbamazepine and rifampicin, as well as oxcarbazepine, topiramate, felbamate and griseofulvin. Specialized studies regarding the interaction of deogestrel with other drugs were not conducted. achieved no earlier than 2-3 weeks after the start of the application of the corresponding inductor up to 4 weeks after its cancellation.
Antibiotics (eg, ampicillin and tetracycline) reduce the effectiveness of oral contraceptives.
Women taking medications that induce liver microsomal enzymes should be recommended to temporarily use additional barrier or other non-hormonal methods of contraception.
With the simultaneous use of the above drugs with desogestrel, it is recommended to use a barrier method of contraception throughout the course of treatment and for 7 days (for rifampicin - 28 days after the end of therapy.
In the treatment with activated carbon, the absorption of steroids, and, consequently, contraceptive efficacy, may decrease. In this case, you should follow the recommendations given in the section "Dosing regimen" for the missed dose of the drug.

Pregnancy and Lactation

During pregnancy, the use of the drug is contraindicated.
In preclinical studies. with the introduction of very high doses of progestogen, masculinization of the female fetus was observed.
Epidemiological studies have not revealed an increased risk of a teratogenic effect and congenital developmental defects among children whose mothers took oral hormonal contraceptives before pregnancy or unintentionally in the early stages of pregnancy.

Lactation period
Like other progestogen containing drugs, Lactinet® does not affect the quality and quantity of breast milk, but a small amount of the metabolite desogestrel (etonogestrel) is excreted in breast milk and is approximately 0.01-0.05 µg / kg / day (when the amount of breast milk consumed is 150 ml / kg / day). The results of a 7-month observation did not reveal increased risks for breastfed infants when assessing their growth, psychomotor and physical development.
However, careful dynamic monitoring of the development and growth of the child during breastfeeding is necessary, if the woman uses Lactinet for contraception® .

Special instructions

If there is any condition or risk factor, the physician must relate the risk and benefit of using Lactinet® individually for each woman before the start of hormonal contraception. In case of occurrence of any undesirable effect or risk factor, it is necessary to immediately notify the attending physician to decide whether to continue taking the drug.
Women with diabetes should be closely monitored during the first months of using Lactinet.®.
Reception Lakinet® reduces serum estradiol to the value corresponding to the early follicular phase.
The protective effect of traditional progestagens containing contraceptives in terms of prevention of ectopic pregnancy is not as pronounced as that of combined oral contraceptives, which is associated with ovulation that occurs relatively frequently while receiving progestogens containing drugs.

Although Lactinet®As a rule, inhibits ovulation, the possibility of ectopic pregnancy should be borne in mind when a differential diagnosis develops in a woman amenorrhea or abdominal pain.
Chloasma can sometimes occur, especially in women with a history of chloasma in pregnant women. Women with a tendency to chloasma should avoid sun and ultraviolet radiation while taking Lactinet®.
Patients with lactose intolerance need to keep in mind that one film-coated tablet Lactinet® contains 67.445 mg of lactose monohydrate. Patients with rare hereditary diseases, such as lactose intolerance, lactase deficiency or glucose-galactose malabsorption should not take the drug.

Influence on ability to drive a car or other working mechanisms
Does not affect the ability to drive a car and working mechanisms.


Signs: nausea, vomiting, bloody discharge / bleeding from the vagina.
Treatment: there is no specific antidote, symptomatic treatment.

  • Brand name: Laknet
  • Active ingredient: Desogestrel
  • Dosage form: film coated pills
  • Manufacturer: Gedeon Richter
  • Country of Origin: Hungary

Studies and clinical trials of Desogestrel (Click to expand)

  1. Enantioselective Total Synthesis of the Oral Contraceptive Desogestrel by a Double Heck Reaction
  2. ChemInform Abstract: A Short Total Synthesis of the Oral Contraceptive Desogestrel
  3. High performance liquid chromatography/ion-trap mass spectrometry for separation and simultaneous determination of ethynylestradiol, gestodene, levonorgestrel, cyproterone acetate and desogestrel
  4. Synthesis of 13-ethyl-11-methylene-18,19-dinor-17α-pregn-4-en-20-yn-17-ol (desogestrel) and its main metabolite 3-oxo desogestrel
  5. Protein S levels are lower in women receiving desogestrel-containing combined oral contraceptives (COCs) than in women receiving levonorgestrel-containing COCs at steady state and on cross-over
  6. A partial synthesis of 13-ethyl-11-methylene-18,19-dinor-17α-pregn-4-en-20-yn-17-ol (desogestrel) based upon intramolecular oxidation of an 11β-hydroxy-19-norsteroid to the 18 → 11β-lactone
  7. Bone mineral density in young women with long-standing amenorrhea: Limited effect of hormone replacement therapy with ethinylestradiol and desogestrel
  8. Desogestrel: using a selective progestogen in a combined oral contraceptive
  9. Evaluation of risk of thrombosis during use of low-dose ethinylestradiol—desogestrel oral contraceptive
  10. Effects of an oral contraceptive combination containing 0.150 mg desogestrel plus 0.020 mg ethinyl estradiol on healthy premenopausal women
  11. Bioavailability and bioequivalence of etonogestrel from two oral formulations of desogestrel: Cerazette® and Liseta®
  12. Virologic failure in an HIV-infected woman given desogestrel for excessive menstrual bleeding
  13. The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel
  14. Effects of ethinyl estradiol and desogestrel on clinical and metabolic parameters in Indian patients with polycystic ovary syndrome
  15. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 μg desogestrel and either 30 μg or 20 μg ethinyl oestradiol
  16. Comparative study of the effects of a progestogen-only pill containing desogestrel and an intrauterine contraceptive device in lactating women
  17. Letrozole and desogestrel-only contraceptive pill for the treatment of stage IV endometriosis
  18. Combined Oral Contraceptive Pills Containing Desogestrel or Drospirenone Enhance Large Vessel and Microvasculature Vasodilation in Healthy Premenopausal Women
  19. Inhibition of antipyrine metabolism by low-dose contraceptives with gestodene and desogestrel
  20. Seventy-Five Microgram Desogestrel Minipill, A New Perspective in Estrogen-Free Contraception
  21. Contraceptive efficacy and acceptability of a monophasic oral contraceptive containing 30 μg ethinyl estradiol and 150 μg desogestrel in Latin-American women
  22. Comparative study on the acceptability of two modern monophasic oral contraceptive preparations: 30 μg ethinyl estradiol combined with 150 μg desogestrel or 75 μg gestodene
  23. Simple, Catalytic Enantioselective Syntheses of Estrone and Desogestrel
  24. Chemosensitivity recovery in Ondine's curse syndrome under treatment with desogestrel

Customers who bought this product also bought:

8 other products in the same category: